



PHOSPHAGENICS

ASX Limited
Market Announcements Office

Phosphagenics' Partner Themis Completes Supply Agreement with Novartis for TPM/Diclofenac Gel

- *Themis Medicare completes manufacturing and supply agreement with Novartis for TPM/diclofenac gel*
- *This is in line with our strategy to expand the TPM[®] technology globally*

15 April 2013, Melbourne: Australian drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) today announced that its commercial partner, Themis Medicare Limited, made the following release to the Bombay Stock Exchange (BSE) post market on Friday 12 April. The release relates to the manufacture and supply of their specially formulated TPM/diclofenac gel to Novartis India Limited.

"License and Supply Agreement

By a License and Supply Agreement between Themis Medicare Limited ("Themis") and Novartis India Limited ("Novartis"), Themis has agreed to manufacture and supply and Novartis has agreed to purchase from Themis diclofenac topical gel formulated using a unique TPM[®] transdermal drug delivery system, in finished dosage pharmaceutical form on certain commercial terms and conditions.

The above drug delivery system is available only with Themis in India."

Novartis India is a subsidiary of the Swiss pharmaceutical company, Novartis International AG, one of the top five pharmaceutical companies in the world. Novartis International AG is the global market leader of diclofenac products with sales exceeding \$700 million for both the transdermal and oral forms.

The endorsement by Novartis India is a significant validation of our TPM[®] technology by a global pharmaceutical company. Phosphagenics welcomes this exciting commercial expansion.

Phosphagenics is focused on leveraging the TPM[®] technology across multiple markets and creating significant global commercial opportunities.

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168

PO Box 1415, Clayton South MDC VIC 3169 Australia

Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151

Web: www.phosphagenics.com Email: info@phosphagenics.com

Ends

Enquiries:

Dr Esra Ogru
Chief Executive Officer
Phosphagenics Limited
+61 3 9565 1119

David Segal
Investor Relations Manager
Phosphagenics Limited
+61 3 9565 1103

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

About Phosphagenics

Phosphagenics Limited is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM[®] – Targeted Penetration Matrix technology. TPM[®] is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone and oxymorphone matrix system for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com
www.elixia.com.au